EUDA Health Holdings Limited — FY2022 Form 10-K
Reporting period: Year ended December 31, 2022; this is an annual report, not a standalone fourth-quarter report. EUDA operates primarily in Singapore, providing medical services and property management services. On November 17, 2022, the SPAC business combination closed, and the company began operating as EUDA Health Holdings Limited.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $9.84 million | $10.54 million |
| Gross profit / margin | $3.35 million / 34.1% | $4.24 million / 40.3% |
| Operating loss | $12.06 million | $1.23 million |
| Net income (loss) | $(24.95) million | $0.90 million |
| Operating cash flow | $(1.53) million | $0.44 million |
| Cash and restricted cash at year-end | $0.78 million | $0.19 million |
- Revenue declined 6.7%. Medical services rose 5.9% to $6.07 million, while property management revenue fell 17.4% to $3.76 million and product sales fell 95.7% to $11,000.
- Gross margin contracted, reflecting higher medical-service costs after a shift from related-party clinic provider Cadence to third-party providers, and higher property-management payroll costs. Lower demand for COVID-era monitoring products also led to inventory write-offs.
- Current assets were $25.03 million and current liabilities $29.12 million, a working-capital deficit of about $4.1 million. The current balances include a $21.89 million forward-purchase receivable and a $20.32 million related liability. Total liabilities were $29.14 million.
- Net loss included a $12.91 million fair-value loss on prepaid forward purchase liabilities, $5.20 million of earnout share expense, $2.87 million of bad-debt provision and $1.14 million of goodwill and intangible impairment. The company fully impaired its goodwill and remaining intangible assets.
- Cash from financing activities was $2.49 million, principally from related-party borrowings, share issuance and business-combination proceeds, partly offset by merger-cost payments. Investing activities used $0.27 million.
Material changes and unusual items
- EUDA reported a swing from FY2021 net income to a substantial FY2022 loss, alongside higher operating expenses and lower gross margin.
- In April 2022, EUDA moved specialty-care services away from related-party provider Cadence toward third-party providers. Cadence-related medical-service costs fell, while third-party costs increased.
- The business combination closed in November 2022. About 6.03 million SPAC shares were redeemed; the company reported approximately $1.32 million of net cash proceeds from the recapitalization. Two forward-purchase arrangements generated a significant year-end receivable and liability, with a large fair-value loss.
- The company wrote off receivables tied to the BPT divestment and a loan to PT Total Prima Indonesia after concluding the balances were unlikely to be collected.
Outlook, risks and contingencies
- The auditor’s report includes a going-concern explanatory paragraph. EUDA cited recurring operating losses and negative operating cash flow since 2020, limited cash, a working-capital deficit and the need for additional funding; the filing says substantial doubt exists about its ability to continue as a going concern.
- Management described potential funding sources including bank or private financing, related-party support and equity financing. Subsequent to year-end, the company received related-party loans, raised $940,000 through a private placement at $1 per share, and settled certain obligations by issuing shares. These measures involve dilution and reliance on related parties.
- Nasdaq had notified the company that late 2022 annual and 2023 first-quarter filings put it out of compliance with timely-reporting rules. Nasdaq accepted a compliance plan requiring the delinquent filings by August 4, 2023; failure could lead to delisting proceedings.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end. Disclosed material weaknesses involved insufficient accounting/reporting personnel with U.S. GAAP expertise and inadequate processes for assessing third-party specialists. Remediation was still in progress.
- EUDA said budgetary and financial constraints pushed planned new health verticals to the second quarter of 2024 at the earliest. The filing describes expansion plans, but does not provide clear consolidated financial guidance.
- Key risks include customer concentration despite no single customer exceeding 10% of revenue, evolving digital-health regulation, privacy and cybersecurity exposure, competition, provider and technology-partner dependence, foreign-exchange movements, and public-company compliance costs. Ordinary-share and warrant trading may also be affected by Nasdaq compliance and price volatility.
- The company reported a Singapore court judgment concerning a related-party loan guarantee; the guarantor was released in October 2022 and the company reported paying approximately $74,966 with no balance outstanding. Other asserted and unasserted claims were not considered material in aggregate.
Important facts for investors to verify
- Confirm the audited statements and resolve an apparent MD&A inconsistency: the results table reports FY2022 gross profit of $3.54 million, while the audited statements and revenue-category table report $3.35 million.
- Review the terms, measurement and subsequent settlement of the forward-purchase agreements. June 2023 amendments accelerated maturity and provided for 1.6 million shares to the sellers; assess resulting dilution and the treatment of the year-end receivable and liability.
- Check the company’s latest cash position, debt maturities, financing completed after year-end, and whether funding is sufficient to address the going-concern uncertainty.
- Verify Nasdaq compliance status and whether the company timely filed all required reports by the stated deadline.
- Track remediation of the disclosed control weaknesses and whether subsequent filings are timely and reliable.
- Assess the assumptions behind the impairment and bad-debt write-offs, as well as the feasibility and funding of the delayed expansion plans.